{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124653","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.016954+00:00","generated_at":"2026-05-30T01:57:53.477496+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cogent Q3 net loss $70.6M; PEAK trial enrolls 413 patients, top-line data in 2025","bullets":["Net loss $70.6M in Q3 2024 vs $55.4M in Q3 2023; cash $345.5M sufficient into late 2026.","Phase 3 PEAK GIST trial completed enrollment (413 patients); IDMC recommended continuation after futility analysis.","Top-line results expected from SUMMIT (2H 2025), APEX (mid-2025), PEAK (end of 2025).","Phase 1 trial initiated for CGT-4859 FGFR2 inhibitor; preclinical data for KRAS and PI3K inhibitors presented.","Inducement grants of options to purchase 132,350 shares to three new employees."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124653","json":"https://secwatch.observer/filing/0000950170-24-124653.json","markdown":"https://secwatch.observer/filing/0000950170-24-124653.md","text":"https://secwatch.observer/filing/0000950170-24-124653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/0000950170-24-124653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017024124653/cogt-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:57:53.477496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}